Wang felt quite positive about Shanghai Pharmaceutical's proposal , but he had to answer quite a few questions in order to move forward: Would this proposal address the issues he was trying to fix? What protocols and steps should he take to ensure that the new partner shared his objectives and create a system that benefited patients? Regarding the new system's development, what were the potential problems in stakeholders' implementation and adoption of the new system? How could he mitigate those risks and successfully put the system into practice? Furthermore, what would be the impact of the "two-invoice" policy on the new proposal